139 related articles for article (PubMed ID: 23114739)
21. Invasive pneumococcal disease and the need for the new 13-valent pneumococcal vaccine.
Bolton M; Barson W
Pediatr Ann; 2010 Aug; 39(8):497-503. PubMed ID: 20704146
[No Abstract] [Full Text] [Related]
22. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.
Wysocki J; Tansey S; Brachet E; Baker S; Gruber W; Giardina P; Arora A
Vaccine; 2010 Nov; 28(49):7779-86. PubMed ID: 20883736
[TBL] [Abstract][Full Text] [Related]
23. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination.
Vila-Córcoles A
J Intern Med; 2009 Nov; 266(5):432-44. PubMed ID: 19754854
[TBL] [Abstract][Full Text] [Related]
24. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.
Poolman J; Borrow R
Expert Rev Vaccines; 2011 Mar; 10(3):307-22. PubMed ID: 21434799
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics of a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine candidate (PHiD-CV). Introduction.
Dagan R; Frasch C
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S63-5. PubMed ID: 19325448
[No Abstract] [Full Text] [Related]
26. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
Weiser JN; Austrian R
Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
[No Abstract] [Full Text] [Related]
27. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009.
Adam D
Vaccine; 2009 Nov; 27(50):7133-7. PubMed ID: 19883868
[TBL] [Abstract][Full Text] [Related]
28. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
30. Vaccine Update: Recommendation for conjugate pneumococcal and pneumococcal polysaccharide vaccines in adults older than 65 years.
Niemi SA; Foster SL; Hayney MS
J Am Pharm Assoc (2003); 2015; 55(2):212, 214-5. PubMed ID: 25749266
[No Abstract] [Full Text] [Related]
31. What is the heterogeneity in the impact seen with pneumococcal conjugate vaccines telling us?
Hausdorff WP; Black S
Vaccine; 2017 Jul; 35(31):3797-3800. PubMed ID: 28619234
[TBL] [Abstract][Full Text] [Related]
32. [Pneumococcal vaccines in adults: an update].
Blamey R
Rev Chilena Infectol; 2014 Oct; 31(5):607-9. PubMed ID: 25491461
[TBL] [Abstract][Full Text] [Related]
33. Pneumococcal vaccines for infants and children--past, present, and future.
Klein JO
Curr Clin Top Infect Dis; 2002; 22():252-65. PubMed ID: 12520657
[No Abstract] [Full Text] [Related]
34. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
35. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
36. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France.
Cohen R; Levy C; Bonnet E; Grondin S; Desvignes V; Lecuyer A; Fritzell B; Varon E
Vaccine; 2010 Aug; 28(37):6114-21. PubMed ID: 19490958
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
Miller E; Andrews NJ; Waight PA; Slack MP; George RC
Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
[TBL] [Abstract][Full Text] [Related]
38. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
39. Authors' reply to Prymula R. Re: "Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines" [Vaccine 27 (2009) 4739-4740].
Rodgers GL; Arguedas A; Cohen R; Dagan R
Vaccine; 2009 Sep; 27(40):5429-30. PubMed ID: 19643215
[No Abstract] [Full Text] [Related]
40. [Medical indications and effectiveness of the pneumococcal conjugate vaccine].
Reinert RR
Laryngorhinootologie; 2006 Apr; 85(4):291-8; quiz 299-300. PubMed ID: 16615030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
